Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis.
Animals
Cell Line, Tumor
Cell Proliferation
Gene Expression Regulation, Neoplastic
Humans
MAP Kinase Signaling System
Melanoma
/ genetics
Mice
Microphthalmia-Associated Transcription Factor
/ genetics
Mitogen-Activated Protein Kinase Kinases
/ metabolism
Proto-Oncogene Proteins B-raf
/ genetics
Quinazolines
BRAFV600E
CK2α
MITF-M
Melanoma metastasis
Tryptanthrin
VEGFR2
β-catenin
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
10 Aug 2022
10 Aug 2022
Historique:
received:
24
01
2022
accepted:
06
07
2022
revised:
04
07
2022
entrez:
10
8
2022
pubmed:
11
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Melanoma is the most aggressive among all types of skin cancers. The current strategies against melanoma utilize BRAF
Identifiants
pubmed: 35948813
doi: 10.1007/s00018-022-04476-y
pii: 10.1007/s00018-022-04476-y
doi:
Substances chimiques
MITF protein, human
0
Microphthalmia-Associated Transcription Factor
0
Quinazolines
0
tryptanthrine
13220-57-0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
478Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Liu Y, Sheikh MS (2014) Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol 6:228
pubmed: 25745537
pmcid: 4346328
Bai X, Fisher DE, Flaherty KT (2019) Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. Nat Rev Clin Oncol 16:549–562
pubmed: 30967646
pmcid: 7185899
Shackelford R, Pollen M, Vora M, Jusion TT, Cotelingam J, Nair B (2014) Malignant melanoma with concurrent BRAF E586K and NRAS Q81K mutations. Case Rep Oncol 7:297–300
pubmed: 24926260
pmcid: 4035678
Tsao H, Chin L, Garraway LA, Fisher DE (2012) Melanoma: from mutations to medicine. Genes Dev 26:1131–1155
pubmed: 22661227
pmcid: 3371404
Wellbrock C, Arozarena I (2016) The complexity of the ERK/MAP-kinase pathway and the treatment of melanoma skin cancer. Front Cell Dev Biol 4:33
pubmed: 27200346
pmcid: 4846800
Kim A, Cohen MS (2016) The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opin Drug Discov 11:907–916
pubmed: 27327499
pmcid: 5443413
Holderfield M, Nagel T, Stuart D (2014) Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer 111:640–645
pubmed: 24642617
pmcid: 4134487
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968–972
pubmed: 21107320
pmcid: 3058384
Hartman ML, Czyz M (2015) Pro-survival role of MITF in melanoma. J Investig Dermatol 135:352–358
pubmed: 25142731
Hartman ML, Czyz M (2015) MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci 72:1249–1260
pubmed: 25433395
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117–122
pubmed: 16001072
Cheli Y, Guiliano S, Botton T, Rocchi S, Hofman V, Hofman P, Bahadoran P, Bertolotto C, Ballotti R (2011) Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30:2307–2318
pubmed: 21278797
Kido K, Sumimoto H, Asada S, Okada SM, Yaguchi T, Kawamura N, Miyagishi M, Saida T, Kawakami Y (2009) Simultaneous suppression of MITF and BRAFV600E enhanced inhibition of melanoma cell proliferation. Cancer Sci 100:1863–1869
pubmed: 19659611
Wellbrock C, Marais R (2005) Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 170:703–708
pubmed: 16129781
pmcid: 2171350
Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565–576
pubmed: 15607961
Johansson CH, Azimi A, Stolt MF, Shojaee S, Wiberg H, Grafström E, Hansson J, Brage SE (2013) Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Res 23:360–365
Smith MP, Wellbrock C (2016) Molecular pathways: maintaining MAPK inhibitor sensitivity by targeting nonmutational tolerance. Clin Cancer Res 22:5966–5970
pubmed: 27797970
pmcid: 5300098
Antony J, Saikia M, Nath L, Katiki MR, Murty M, Paul A, Chandran H, Joseph SM, Panakkal EJ, Ran S (2015) DW-F5: a novel formulation against malignant melanoma from Wrightia tinctoria. Sci Rep 5:1–15
Shankar GM, Alex VV, Nisthul AA, Bava SV, Sundaram S, Retnakumari AP, Chittalakkottu S, Anto RJ (2020) Pre-clinical evidences for the efficacy of tryptanthrin as a potent suppressor of skin cancer. Cell Prolif 53:e12710
Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Chabert C, Boschert U, Arkinstall S (1998) Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 280:1262–1265
pubmed: 9596579
Castelli M, Camps M, Gillieron C, Leroy D, Arkinstall S, Rommel C, Nichols A (2004) MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2α. J Biol Chem 279:44731–44739
pubmed: 15284227
Borgo C, Ruzzene M (2019) Role of protein kinase CK2 in antitumor drug resistance. J Exp Clin Cancer Res 38:1–15
Alchab F, Ettouati L, Bouaziz Z, Bollacke A, Delcros J-G, Gertzen CG, Gohlke H, Pinaud N, Marchivie M, Guillon J (2015) Synthesis, biological evaluation and molecular modeling of substituted indeno [1, 2-b] indoles as inhibitors of human protein kinase CK2. Pharmaceuticals 8:279–302
pubmed: 26061121
pmcid: 4491662
Bollacke A, Nienberg C, Le Borgne M, Jose J (2016) Toward selective CK2alpha and CK2alpha’inhibitors: development of a novel whole-cell kinase assay by autodisplay of catalytic CK2alpha’. J Pharm Biomed Anal 121:253–260
pubmed: 26786382
Thiel A, Moza M, Kytölä S, Orpana A, Jahkola T, Hernberg M, Virolainen S, Ristimäki A (2015) Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. Hum Pathol 46:169–175
pubmed: 25442222
Alcalá AM, Flaherty KT (2012) BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 18:33–39
pubmed: 22215904
Salama AK, Flaherty KT (2013) BRAF in melanoma: current strategies and future directions. Clin Cancer Res 19:4326–4334
pubmed: 23770823
Ji Z, Flaherty KT, Tsao H (2012) Targeting the RAS pathway in melanoma. Trends Mol Med 18:27–35
pubmed: 21962474
Welsh SJ, Rizos H, Scolyer RA, Long GV (2016) Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next? Eur J Cancer 62:76–85
pubmed: 27232329
Kataoka M, Hirata K, Kunikata T, Ushio S, Iwaki K, Ohashi K, Ikeda M, Kurimoto M (2001) Antibacterial action of tryptanthrin and kaempferol, isolated from the indigo plant (Polygonum tinctorium Lour.), against Helicobacter pylori-infected Mongolian gerbils. J Gastroenterol 36:5–9
pubmed: 11211212
Kaur R, Manjal SK, Rawal RK, Kumar K (2017) Recent synthetic and medicinal perspectives of tryptanthrin. Bioorg Med Chem 25:4533–4552
pubmed: 28720329
Miao S, Shi X, Zhang H, Wang S, Sun J, Hua W, Miao Q, Zhao Y, Zhang C (2011) Proliferation-attenuating and apoptosis-inducing effects of tryptanthrin on human chronic myeloid leukemia K562 cell line in vitro. Int J Mol Sci 12:3831–3845
pubmed: 21747710
pmcid: 3131594
Yu S-T, Chen T-M, Tseng S-Y, Chen Y-H (2007) Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 358:79–84
pubmed: 17482571
Zeng Q, Luo C, Cho J, Lai D, Shen X, Zhang X, Zhou W (2021) Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment. Acta Pharm 71:245–266
pubmed: 33151167
Levy C, Khaled M, Fisher DE (2006) MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12:406–414
pubmed: 16899407
Aida S, Sonobe Y, Tanimura H, Oikawa N, Yuhki M, Sakamoto H, Mizuno T (2017) MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor. Cancer Lett 409:116–124
pubmed: 28923400
Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP (2016) Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell 29:270–284
pubmed: 26977879
pmcid: 4796027
Switzer B, Puzanov I, Skitzki JJ, Hamad L, Ernstoff MS (2022) Managing metastatic melanoma in 2022: a clinical review. JCO Oncol Pract 2022:OP. 21.00686
Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR (2016) MAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPNMB. Clin Cancer Res 22:6088–6098
pubmed: 27515299
pmcid: 6168941
Arozarena I, Smith MP, Wellbrock C (2016) Targeting MITF in the tolerance-phase. Oncotarget 7:54094
pubmed: 27528022
pmcid: 5342328
Kundu A, Quirit JG, Khouri MG, Firestone GL (2017) Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation. Mol Carcinog 56:49–61
pubmed: 26878440
Yokoyama S, Feige E, Poling LL, Levy C, Widlund HR, Khaled M, Kung AL, Fisher DE (2008) Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21:457–463
pubmed: 18627530
pmcid: 3771662
Faloon PW, Bennion M, Weiner WS, Smith RA, Wurst J, Weiwer M, Hartland C, Mosher CM, Johnston S, Porubsky P (2014) A small molecule inhibitor of the MITF molecular pathway. Probe reports from the NIH Molecular Libraries Program [Internet] 2014
Joshi SS, Hornyak TJ (2020) Cellular phenotypic plasticity of cutaneous melanoma: a complex puzzle. J Investig Dermatol 140:743–745
pubmed: 32200877
Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R (2008) Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3:e2734
pubmed: 18628967
pmcid: 2444043
Kim Y, Rice AE, Denu JM (2003) Intramolecular dephosphorylation of ERK by MKP3. Biochemistry 42:15197–15207
pubmed: 14690430